- About Us
- Clinical Trials
- News & Publications
- Business Development
June 15, 2020
Source: Press Release
SOTIO, a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial for the treatment of advanced solid tumors, in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held from June 22-24, 2020.
Poster presentation details
Abstract: 6686 / 2
Session: Session PO.IM02.20 - Immunomodulatory Agents and Interventions 3
Date/Time: Monday, June 22, 2020, 9:00 a.m. – 6:00 p.m. EDT
A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes.
Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the Phase 1 clinical trial.